Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/art.39104 http://scihub22266oqcxt.onion/10.1002/art.39104 C5956529!5956529!25776953     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Arthritis+Rheumatol 2015 ; 67 (6): 1629-36 Nephropedia Template TP {{tp|p=25776953|t=2015. Outcomes of Non-Severe Relapses in ANCA-Associated Vasculitis Treated with Glucocorticoids |pdf=|usr=}}{{25776953}} gab.com Text Outcomes of Non-Severe Relapses in ANCA-Associated Vasculitis Treated with Glucocorticoids JO: Arthritis Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=25776953 #FOAvip Objective: Non-severe relapses are more common than severe relapses in ANCA-associated vasculitis (AAV), but their clinical course and treatment outcomes remain largely unexamined. We analyzed the outcomes of non-severe relapses in the Rituximab in AAV (RAVE) trial that were treated according to a pre-specified prednisone protocol. Methods: RAVE was a randomized, double-blind, placebo-controlled trial comparing rituximab (RTX) to cyclophosphamide (CYC) followed by azathioprine (AZA) for remission induction. Patients who experienced non-severe relapses between months 1 and 18 were treated with a prednisone increase without a concomitant change in their non-glucocorticoid immunosuppressants, followed by a taper. Results: Forty-four patients with a first non-severe relapse were analyzed. In comparison to the 71 patients who maintained relapse-free remission over 18 months, these patients were more likely to have PR3-ANCA, diagnoses of GPA, and relapsing disease at baseline. A prednisone increase led to remission in 35 patients (80%). However, only 13 patients (30%) were able to maintain second remissions through the follow-up period (mean 12.5 months); 31 (70%) relapsed again ? 14 with severe disease. The mean time to second relapse was 9.4 months (4.7 RTX, 13.7 CYC/AZA [p<0.01]). Patients who experienced non-severe relapses received more glucocorticoids than those who maintained remission (6.7 grams versus 3.8 grams [p<0.01]). Conclusion: Treatment of non-severe relapses in AAV with an increase in glucocorticoids is effective in restoring temporary remission in the majority of patients, but recurrent relapses within a relatively short interval are the rule. Alternative treatment approaches for this important subset of patients are needed. Twit Text FOAVip Outcomes of Non-Severe Relapses in ANCA-Associated Vasculitis Treated with Glucocorticoids ????Arthritis Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=25776953 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25776953 #FOAvip English Wikipedia <ref>{{Cite pmid|25776953}}</ref> Outcomes of Non-Severe Relapses in ANCA-Associated Vasculitis Treated with Glucocorticoids #MMPMID25776953 Miloslavsky E; Specks U; Merkel P; Seo P; Spiera R; Langford C; Hoffman G; Kallenberg C; St. Clair E; Tchao N; Ding L; Ikle D; Villareal M; Lim N; Brunetta P; Fervenza F; Monach P; Stone J Arthritis Rheumatol 2015[Jun]; 67 (6): 1629-36 PMID25776953show ga Objective: Non-severe relapses are more common than severe relapses in ANCA-associated vasculitis (AAV), but their clinical course and treatment outcomes remain largely unexamined. We analyzed the outcomes of non-severe relapses in the Rituximab in AAV (RAVE) trial that were treated according to a pre-specified prednisone protocol. Methods: RAVE was a randomized, double-blind, placebo-controlled trial comparing rituximab (RTX) to cyclophosphamide (CYC) followed by azathioprine (AZA) for remission induction. Patients who experienced non-severe relapses between months 1 and 18 were treated with a prednisone increase without a concomitant change in their non-glucocorticoid immunosuppressants, followed by a taper. Results: Forty-four patients with a first non-severe relapse were analyzed. In comparison to the 71 patients who maintained relapse-free remission over 18 months, these patients were more likely to have PR3-ANCA, diagnoses of GPA, and relapsing disease at baseline. A prednisone increase led to remission in 35 patients (80%). However, only 13 patients (30%) were able to maintain second remissions through the follow-up period (mean 12.5 months); 31 (70%) relapsed again ? 14 with severe disease. The mean time to second relapse was 9.4 months (4.7 RTX, 13.7 CYC/AZA [p<0.01]). Patients who experienced non-severe relapses received more glucocorticoids than those who maintained remission (6.7 grams versus 3.8 grams [p<0.01]). Conclusion: Treatment of non-severe relapses in AAV with an increase in glucocorticoids is effective in restoring temporary remission in the majority of patients, but recurrent relapses within a relatively short interval are the rule. Alternative treatment approaches for this important subset of patients are needed. äOutcomes of Non-Severe Relapses in ANCA-Associated Vasculitis Treated (epmc).pdf DeepDyve Pubget Overpricing